ClinicalTrials.gg
RecruitingNCT05266144Updated Nov 3, 2026

Atrial Fibrillation Patients Treated With Catheter Ablation

An observational study in Atrial Fibrillation and Atrial Fibrillation Recurrent, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.
Updated Nov 3, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
75th of 121
300 · median 500
Started
2020
with 22 others
Observational
121 of 377
48 open now
Primary completion
2027-10
later than 125 of 182 live
Registered
149th of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 75th largest by planned enrollment of the 121 observational ones that give a count, is one of 23 that started in 2020, is one of 121 observational ones, reaches primary completion later than 125 of the 182 other live ones, and was the 149th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

This is a single-center prospective observational cohort study of atrial fibrillation patients treated with radiofrequency ablation.

Read the detailed description

The effect of radiofrequency therapy on the life quality and atrial function of atrial fibrillation patients will be assessed, through the multidimensional analysis of baseline clinical data, serological indicators of atrial fibrosis, echocardiography, cardiac magnetic resonance imaging, atrial potential mapping, life quality, and long-term ECG monitoring within 1 week after radiofrequency ablation. A predictive model for atrial fibrillation recurrence after ablation will be established. Based on the cross-sectional analysis of baseline data, the relationship between non-invasive assessment of atrial fibrosis (imaging and serology), atrial electrical activity, and atrial function will be analyzed as well, and atrial fibrillation patients with ventricular fibrosis will be selected for gene sequencing to explore the existence of underlying cardiomyopathy and provide data for further research.

03

Conditions studied

  • Atrial Fibrillation
  • Atrial Fibrillation Recurrent

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive atrial fibrillation patients, who underwent catheter ablation in Peking Union Medical College Hospital, were enrolled. All patients went through bilateral pulmonary vein isolation under general or local anesthesia, and were regularly followed up at 3-month and 1-year after ablation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-valvular atrial fibrillation, including paroxysmal atrial fibrillation and persistent atrial fibrillation
  • 18-80 years old
  • The anteroposterior diameter of the left atrium is less than 50mm via TTE
  • Patient meets the intervention criteria for bilateral pulmonary vein isolation after evaluation by electrophysiological specialists
  • Patient consents to ablation treatment

Exclusion criteria

Exclusion Criteria:

  • Intra-atrial thrombus detected by TEE
  • Hyperthyroidism
  • Previous radiofrequency ablation for atrial fibrillation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • atrial fibrillation

    Atrial fibrillation patients who underwent radiofrequency ablation in Peking Union Medical College Hospital.

    Procedure: radiofrequency ablation

Interventions

  • Procedureradiofrequency ablation

    Bilateral pulmonary vein isolation, a kind of radiofrequency ablation, is performed in atrial fibrillation patients for atrial arrhythmia therapy.

06

What researchers measure

Primary outcomes

  1. Recurrence assessed by ECG, Holter reports and outpatient physicians

    Recurrence includes atrial fibrillation and atrial flutter. Recurrence features including pattern, duration, burden, etc. will be recorded.

    Time frame: at 1-year follow-up after ablation

  2. All-cause mortality assessed by telephone follow-up or medical records

    Time and cause of death will be recorded.

    Time frame: at 1-year follow-up after ablation

Secondary outcomes

  1. Improvement in life quality assessed by QOLSF36 Questionnaire

    Life quality will be assessed at baseline and 1-year FU. Improvement in life quality indicates that patients can benefit from the catheter ablation.

    Time frame: at 1-year follow-up after ablation

  2. Improvement in left atrial function assessed by echocardiography

    Left atrial function will be assessed at baseline and 1-year FU. Improvement in atrial function indicates that ablation can restore atrial function.

    Time frame: at 1-year follow-up after ablation

  3. Embolic events assessed by physicians and further examinations like ultrasound, MRI

    Embolism may be related to atrial fibrillation. Embolism will be assessed by physicians according to patients' symptoms and signs at clinic or by telephone. If a patient's clinical presentation indicates embolism, the patient will be further assessed by ultrasound, MRI, etc.

    Time frame: at 1-year follow-up after ablation

  4. Hospitalization for heart failure, atrial fibrillation or atrial flutter

    Postoperative hospitalization indicate worse prognosis.

    Time frame: at 1-year follow-up after ablation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lai J, Qin X, Zhang D, Wang J, Yu J, Sun K, Yang D, Fan J, Zhang L, Cheng Z, Cheng K, Gao P, Deng H, Fang L, Chen T, Fang Q, Liu Y. The diagnostic value of left atrial stiffness for heart failure with preserved ejection fraction in patients with paroxysmal atrial fibrillation. Echo Res Pract. 2026 Feb 23;13(1):6. doi: 10.1186/s44156-026-00107-5. PubMed 41725017 ↗
  • Sun K, Qin X, Zhang D, Fang F, Wan R, Wang J, Yu J, Lai J, Yang D, Fan J, Cheng Z, Cheng K, Gao P, Zhang L, Deng H, Fang Q, Chen T, Liu Y. HFpEF correlated with better improvement of left atrial function in post-ablation patients with paroxysmal atrial fibrillation. Int J Cardiovasc Imaging. 2025 Apr;41(4):721-732. doi: 10.1007/s10554-025-03359-0. Epub 2025 Mar 1. PubMed 40025277 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Oct 2027, 84 months after the start.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 84 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Oct 2025 → Oct 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2022
First posted
Mar 4, 2022
StartActual
Sep 4, 2020
Primary completionEst.
Oct 1, 2027was Oct 2025
CompletionEst.
Dec 31, 2027was Dec 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Peking Union Medical College Hospital · Beijing, China
Show 1 removed
  • Peking Union Medical College Hospital · Beijing, China
Nov 3, 2026
Primary completion
Oct 1, 2025→Oct 1, 2027
Nov 3, 2026
Study completion
Dec 31, 2025→Dec 31, 2027
Nov 3, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 41725017 ↗
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 41725017 ↗
    1 site added, 1 site removed
    Show site
    • Peking Union Medical College Hospital · Beijing, China
    Show 1 removed
    • Peking Union Medical College Hospital · Beijing, China
    Primary completion Oct 1, 2025→Oct 1, 2027
    Study completion Dec 31, 2025→Dec 31, 2027
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05266144
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Sep 4, 2020
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Yongtai Liu, M.D.
Contact
ataiever@163.com
+86-1069155068
Quan Fang, M.D.
study chair · Peking Union Medical College Hospital
Yongtai Liu, M.D.
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion